Squamous cell carcinoma of the eyelid (SCC) is the second most common malignancy of the eyelid. Treatment: The main treatment is extensive and complete surgical resection. Other therapies: Radiation therapy: Unlike basal cell carcinoma which is sensitive to radiation therapy, it is usually combined with radiation therapy after surgical resection. If the tumor area is too large, radiation therapy can be given first to shrink the tumor tissue to facilitate surgical resection. Li Yangjun, Ophthalmology, Tangdu Hospital, Fourth Military Medical University Chemotherapy: can be used in combination with surgical therapy radiotherapy. Hematoporphyrin derivative-laser photodynamic therapy has good effect. Immunotherapy: same as basal cell carcinoma. Cryotherapy: freezing with liquid nitrogen, the scope of which should cross the edge of tumor more than 4-5 mm, 2-5 minutes each time, once every 2-3 days. Prognosis: Factors affecting prognosis: High risk factors for eyelid SCC are: lesions larger than 2 cm, poor tissue differentiation, deep invasion of tissue, and invasion of peripheral nerves. Recurrent tumors, occurrence on a scar, or immunocompromised individuals suggest a poor prognosis. Metastasis: SCC has local invasion, metastasis to local lymph nodes, and distant metastasis via hematology and lymph.